› 1csj

X-ray diffraction
2.8Å resolution

CRYSTAL STRUCTURE OF THE RNA-DEPENDENT RNA POLYMERASE OF HEPATITIS C VIRUS

Released:
DOI: 10.2210/pdb1csj/pdb
PDB entry 1csj coloured by chain, front view.
PDB entry 1csj coloured by chain, side view.
PDB entry 1csj coloured by chain, top view.
Source organism: Hepacivirus hominis
Primary publication:
Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus.
Bressanelli S, Tomei L, Roussel A, Incitti I, Vitale RL, Mathieu M, De Francesco R, Rey FA
Proc Natl Acad Sci U S A 96 13034-9 (1999)
PMID: 10557268

Function and Biology Details

Reactions catalysed: 
Nucleoside triphosphate + RNA(n) = diphosphate + RNA(n+1)
Hydrolysis of four peptide bonds in the viral precursor polyprotein, commonly with Asp or Glu in the P6 position, Cys or Thr in P1 and Ser or Ala in P1'.
NTP + H(2)O = NDP + phosphate
ATP + H(2)O = ADP + phosphate
Biochemical function:
Biological process:
Cellular component:
  • not assigned
Sequence domains:
Structure domain:

Structure analysis Details

Assembly composition:
homo dimer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-150815 (preferred)
Entry contents:
1 distinct polypeptide molecule
Macromolecule:
RNA-directed RNA polymerase Chains: A, B
Molecule details ›
Chains: A, B
Length: 531 amino acids
Theoretical weight: 59.45 KDa
Source organism: Hepacivirus hominis
Expression system: Escherichia coli
UniProt:
  • Canonical: P26663 (Residues: 2420-2950; Coverage: 18%)
Sequence domains: Viral RNA dependent RNA polymerase
Structure domains: Alpha-Beta Plaits

Ligands and Environments

No bound ligands
1 modified residue:
Ligand MSE 24 x MSE

Experiments and Validation Details

Entry percentile scores
X-ray source: ESRF BEAMLINE BM14
Spacegroup: P212121
Unit cell:
a: 67.063Å b: 96.895Å c: 194.432Å
α: 90° β: 90° γ: 90°
R-values:
R R work R free
0.237 0.237 0.286
Expression system: Escherichia coli

Quick links

Citations

69 review citations

Structural biology of hepatitis C virus.
Penin et al. (2004)
68 more

6 mentions without citation

Anti-HCV drugs in the pipeline.
Yang et al. (2011)
5 more